Total Payments
$314,211
2024 Payments
$52,756
Companies
94
Transactions
1,998
Medicare Patients
11,792
Medicare Billing
$1.5M
Payment Breakdown by Category
Other$221,540 (70.5%)
Food & Beverage$41,181 (13.1%)
Travel$36,910 (11.7%)
Consulting$14,031 (4.5%)
Education$548.07 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $212,708 | 101 | 67.7% |
| Food and Beverage | $41,181 | 1,802 | 13.1% |
| Travel and Lodging | $36,910 | 55 | 11.7% |
| Consulting Fee | $14,031 | 16 | 4.5% |
| Compensation for serving as faculty or as a speaker for a medical education program | $8,742 | 3 | 2.8% |
| Education | $548.07 | 19 | 0.2% |
| Entertainment | $90.12 | 2 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Esperion Therapeutics, Inc. | $171,447 | 187 | $0 (2024) |
| HARMONY BIOSCIENCES LLC | $56,949 | 199 | $0 (2024) |
| IDORSIA PHARMACEUTICALS US INC | $25,563 | 56 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $21,454 | 96 | $0 (2024) |
| Merck Sharp & Dohme LLC | $8,430 | 78 | $0 (2024) |
| Amgen Inc. | $4,154 | 103 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $2,207 | 98 | $0 (2024) |
| Biohaven Pharmaceuticals, Inc. | $1,470 | 7 | $0 (2021) |
| Optinose US, Inc. | $1,445 | 20 | $0 (2024) |
| Lilly USA, LLC | $1,379 | 85 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $52,756 | 431 | JAZZ PHARMACEUTICALS INC. ($17,328) |
| 2023 | $45,324 | 313 | IDORSIA PHARMACEUTICALS US INC ($25,307) |
| 2022 | $62,411 | 293 | Esperion Therapeutics, Inc. ($43,704) |
| 2021 | $98,186 | 247 | Esperion Therapeutics, Inc. ($84,350) |
| 2020 | $39,099 | 194 | Esperion Therapeutics, Inc. ($26,837) |
| 2019 | $3,024 | 153 | Lilly USA, LLC ($299.37) |
| 2018 | $3,209 | 182 | AstraZeneca Pharmaceuticals LP ($342.20) |
| 2017 | $10,202 | 185 | Merck Sharp & Dohme Corporation ($7,399) |
All Payment Transactions
1,998 individual payment records from CMS Open Payments — Page 1 of 80
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | Harmony Biosciences Llc | WAKIX (Drug) | Food and Beverage | Cash or cash equivalent | $26.16 | General |
| Category: Narcoplepsy | ||||||
| 12/31/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $15.88 | General |
| Category: Gastroenterology | ||||||
| 12/28/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $24.39 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/27/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $24.39 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/23/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $15.40 | General |
| Category: Gastroenterology | ||||||
| 12/21/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $16.12 | General |
| Category: Endocrinology | ||||||
| 12/19/2024 | iRhythm Technologies, Inc. | Zio monitor (Device), ZIO XT Patch | Food and Beverage | In-kind items and services | $23.92 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/19/2024 | Azurity Pharmaceuticals, Inc. | HORIZANT (Drug) | Food and Beverage | In-kind items and services | $14.62 | General |
| Category: CEREBROVASCULARCNS | ||||||
| 12/18/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $22.50 | General |
| Category: Cardiology | ||||||
| 12/18/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $9.31 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/17/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $24.39 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 12/17/2024 | Harmony Biosciences Llc | WAKIX (Drug) | Food and Beverage | Cash or cash equivalent | $17.59 | General |
| Category: Narcoplepsy | ||||||
| 12/16/2024 | Xeris Pharmaceuticals, Inc. | RECORLEV (Drug) | Food and Beverage | In-kind items and services | $23.70 | General |
| Category: Adrenal steroidogenesis inhibitor | ||||||
| 12/16/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $13.50 | General |
| Category: NEUROLOGY | ||||||
| 12/12/2024 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $20.79 | General |
| Category: UROLOGY | ||||||
| 12/11/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $30.60 | General |
| Category: Psychology/Psychiatric | ||||||
| 12/11/2024 | Azurity Pharmaceuticals, Inc. | HORIZANT (Drug) | Food and Beverage | In-kind items and services | $10.17 | General |
| Category: CEREBROVASCULARCNS | ||||||
| 12/11/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $9.66 | General |
| Category: Cardiology | ||||||
| 12/10/2024 | HARMONY BIOSCIENCES LLC | WAKIX (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $2,814.00 | General |
| Category: Narcoplepsy | ||||||
| 12/10/2024 | HARMONY BIOSCIENCES LLC | WAKIX (Drug) | Food and Beverage | Cash or cash equivalent | $125.01 | General |
| Category: Narcoplepsy | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $25.92 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/10/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $10.50 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/05/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $27.62 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/05/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $27.62 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/05/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $19.97 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 52 | 2,670 | 8,204 | $1.0M | $379,624 |
| 2022 | 55 | 3,777 | 11,402 | $1.2M | $461,022 |
| 2021 | 41 | 2,913 | 8,251 | $797,178 | $385,614 |
| 2020 | 43 | 2,432 | 7,509 | $727,601 | $316,144 |
Total Patients
11,792
Total Services
35,366
Medicare Billing
$1.5M
Procedure Codes
191
All Medicare Procedures & Services
191 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 295 | 874 | $249,253 | $98,276 | 39.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 320 | 679 | $131,800 | $52,382 | 39.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 116 | 185 | $68,096 | $29,157 | 42.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 21 | 1,620 | $70,096 | $29,035 | 41.4% |
| 95800 | Sleep study including heart rate, breathing, and sleep time | Office | 2023 | 147 | 197 | $78,962 | $24,523 | 31.1% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Office | 2023 | 35 | 35 | $52,753 | $21,587 | 40.9% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Office | 2023 | 13 | 37 | $36,058 | $15,661 | 43.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 85 | 85 | $36,225 | $12,683 | 35.0% |
| J3304 | Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg | Office | 2023 | 15 | 896 | $29,110 | $11,964 | 41.1% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 32 | 32 | $16,182 | $8,994 | 55.6% |
| 95810 | Sleep study in sleep lab (6 years or older) | Office | 2023 | 12 | 12 | $16,864 | $7,067 | 41.9% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 79 | 79 | $13,825 | $5,989 | 43.3% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 37 | 37 | $22,002 | $5,441 | 24.7% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 29 | 29 | $15,008 | $5,239 | 34.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 207 | 606 | $14,592 | $5,074 | 34.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 107 | 336 | $13,344 | $4,292 | 32.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 29 | 29 | $12,107 | $3,891 | 32.1% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 78 | 78 | $3,900 | $2,806 | 72.0% |
| 76770 | Complete ultrasound scan behind abdominal cavity | Office | 2023 | 29 | 30 | $7,729 | $2,776 | 35.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 13 | 13 | $6,710 | $2,694 | 40.1% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2023 | 58 | 432 | $8,720 | $2,544 | 29.2% |
| 87428 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus and influenza | Office | 2023 | 57 | 84 | $12,480 | $2,498 | 20.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 26 | 26 | $7,860 | $2,353 | 29.9% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 20 | 24 | $5,624 | $2,222 | 39.5% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 35 | 41 | $5,503 | $2,198 | 39.9% |
About Dr. Jonathan Lown, MD
Dr. Jonathan Lown, MD is a Sleep Medicine healthcare provider based in Commack, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1265538458.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jonathan Lown, MD has received a total of $314,211 in payments from pharmaceutical and medical device companies, with $52,756 received in 2024. These payments were reported across 1,998 transactions from 94 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($212,708).
As a Medicare-enrolled provider, Lown has provided services to 11,792 Medicare beneficiaries, totaling 35,366 services with total Medicare billing of $1.5M. Data is available for 4 years (2020–2023), covering 191 distinct procedure/service records.
Ad
Practice Information
- Specialty Sleep Medicine
- Other Specialties Durable Medical Equipment & Medical Supplies, Internal Medicine
- Location Commack, NY
- Active Since 09/15/2006
- Last Updated 02/03/2020
- Taxonomy Code 207RS0012X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1265538458
Products in Payments
- NEXLIZET (Drug) $165,405
- Wakix (Drug) $31,217
- WAKIX (Drug) $25,732
- QUVIVIQ (Drug) $25,563
- XYWAV (Drug) $20,907
- BELSOMRA (Drug) $7,693
- NEXLETOL (Drug) $6,042
- Repatha (Biological) $2,755
- FARXIGA (Drug) $1,911
- NURTEC ODT (Drug) $1,780
- Xhance (Drug) $1,445
- XIFAXAN (Drug) $1,416
- GEMTESA (Drug) $855.75
- Zilretta (Drug) $818.02
- CAPLYTA (Drug) $801.34
- VRAYLAR (Drug) $786.81
- Kerendia (Drug) $670.78
- Vascepa (Drug) $642.02
- TRULICITY (Drug) $625.77
- LEQVIO (Drug) $552.11
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.